ClinicalTrials.gg
CompletedNCT02310750Updated Mar 8, 2017Results posted

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

A Phase 1 interventional study of PF-06700841 oral solution/suspension and Placebo in Plaque Psoriasis, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.

Enrollment
24th of 42
96 · median 120
Started
2014
with 3 others
Phase 1
10 of 57
none open now
Registered
48th of 57
by date

Among the 57 studies in Psoriasis by Pfizer, this one is the 24th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2014, is one of 10 in phase 1, and was the 48th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Psoriasis by Pfizer as a file.
02

Study summary

The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key Inclusion Criteria for Healthy Subject Cohorts:

  • Healthy male subjects and/or female subjects of non- between the ages of 18 and 55 years, inclusive
  • No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Key Inclusion Criteria for Psoriasis Subject Cohorts:

  • Male subjects and/or female subjects of non-childbearing potential with a diagnosis of plaque psoriasis who are between the ages of 18 and 65 years, inclusive
  • Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose

Exclusion criteria

Exclusion Criteria:

Key Exclusion Criteria for Healthy Subject Cohorts:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  • Males of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of product

Key Exclusion Criteria for Psoriasis Subject Cohorts:

  • Currently have non plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustular psoriasis).
  • Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium
  • Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    PF-06700841 Oral Solution/Suspension

    Drug: PF-06700841 oral solution/suspension

  • Experimental
    PF-06700841 Tablet

    Drug: PF-06700841 tablet

  • Placebo comparator
    Placebo

    Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.

    Other: Placebo

Interventions

  • DrugPF-06700841 oral solution/suspension

    Drug page: PF-06700841

    Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)

  • OtherPlacebo

    Matching placebo given during the single ascending and multiple dose periods

  • PF-06700841 tablet formulation administered during the bioavailability / food effect investigation

06

What researchers measure

Primary outcomes

  1. Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1

    Time frame: Baseline, 24 hours post-dose on Day 1

  2. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10

    Time frame: Baseline, 16 hours post-dose on Day 10

  3. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28

    Time frame: Baseline, 16 hours post-dose on Day 28

  4. Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1

    Time frame: Baseline, 24 hours post-dose on Day 1

  5. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10

    Time frame: Baseline, 16 hours post-dose on Day 10

  6. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28

    Time frame: Baseline, 16 hours post-dose on Day 28

  7. Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1

    Time frame: Baseline, 24 hours post-dose on Day 1

  8. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10

    Time frame: Baseline, 16 hours post-dose on Day 10

  9. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28

    Time frame: Baseline, 16 hours post-dose on Day 28

  10. Number of Participants With Change From Baseline in Physical Examinations

    Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.

    Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37

  11. Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1

    Time frame: Baseline, 24 hours post-dose on Day 1

  12. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10

    Time frame: Baseline, 16 hours post-dose on Day 10

  13. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28

    Time frame: Baseline, 16 hours post-dose on Day 28

  14. Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1

    Time frame: Baseline, 24 hours post-dose on Day 1

  15. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10

    Time frame: Baseline, 16 hours post-dose on Day 10

  16. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28

    Time frame: Baseline, 16 hours post-dose on Day 28

  17. Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.

    Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37

  18. Number of Adverse Events (AEs) According to Severity

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.

    Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37

  19. Number of Participants With Laboratory Abnormalities

    Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\<) 0.8\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \<0.9\*LLN,\>1.1\*upper limit of normal (ULN); platelets: \<0.5\*LLN,\>1.75\*ULN, white blood cell count: \<0.6\*LLN, \>1.5\*ULN; lymphocytes, total neutrophils: \<0.8\*LLN, \>1.2\*ULN; eosinophils, basophils, monocytes: \>1.2\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \>1.1\*ULN; liver function: bilirubin: \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\*ULN; protein, albumin: \<0.8\*LLN\>\</0\>1.2\*ULN; renal function:blood urea nitrogen,creatinine: \>1.3\*ULN; uric acid: \>1.2\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN,\>1.1\*ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\*LLN,\>1.5\*ULN)

    Time frame: SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37

  20. Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1

    Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

    Time frame: Baseline, 24 hours post-dose on Day 1

  21. Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10

    Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

    Time frame: Baseline, 16 hours post-dose on Day 10

  22. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28

    Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

    Time frame: Baseline, 16 hours post-dose on Day 28

  23. Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1

  24. Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841

    Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).

    Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1

  25. Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841

    Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1

Secondary outcomes

  1. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841

    Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28

  2. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841

    Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28

  3. Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841

    Time frame: Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1

  4. Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

    Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1

  5. Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841

    Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.

    Time frame: MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28

  6. Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841

    Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).

    Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1

  7. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841

    Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.

    Time frame: SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28

  8. Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.

    Time frame: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1

  9. Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841

    Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1

  10. Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841

    Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.

    Time frame: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10

  11. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841

    Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.

    Time frame: SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28

  12. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841

    MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.

    Time frame: SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28

  13. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28

  14. Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.

    Time frame: SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28

  15. Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841

    PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\[tau\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.

    Time frame: MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28

  16. Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)

    Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

    Time frame: 0-24 hour on Day 10

  17. Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)

    Aetau% was calculated as: 100\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

    Time frame: 0-24 hours on Day 10

  18. Multiple Ascending Dose (MAD) Cohort: Renal Clearance

    Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

    Time frame: 0-24 hours on Day 10

  19. Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline

    Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.

    Time frame: Baseline

  20. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28

    Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.

    Time frame: Baseline, Day 2, 5, 10, 11, 28

  21. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56

    Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.

    Time frame: Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56

  22. Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline

    Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

    Time frame: Baseline

  23. Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28

    Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

    Time frame: Baseline, Day 2, 5, 10, 11, 28

  24. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56

    Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

    Time frame: Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56

  25. Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8

    Time frame: Baseline, Day 2, 5, 8

  26. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28

    Time frame: Baseline, Day 4, 8, 10, 11, 14, 28

  27. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56

    Time frame: Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56

  28. Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8

    Time frame: Baseline, Day 2, 5, 8

  29. Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28

    Time frame: Baseline, Day 4, 8, 10, 11, 14, 28

  30. Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56

    Time frame: Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56

07

Results

Posted Mar 8, 2017

Participant flow

HP Period 1
Participant flow — HP Period 1
MilestonePF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution FastedPF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet FedPF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet FastedPF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet FedPF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet FastedPF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted
Started76668813000222222
Completed66658812000222222
Not completed1001001000000000
Withdrew: Lost to follow-up0000001000000000
Withdrew: Withdrawal by subject1001000000000000
HP Washout 1
Participant flow — HP Washout 1
MilestonePF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution FastedPF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet FedPF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet FastedPF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet FedPF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet FastedPF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted
Started00658812000222222
Completed0054669000222222
Not completed0011223000000000
Withdrew: Lost to follow-up0011223000000000
HP MAD, Psoriasis MD, HP Fasted/Fed
Participant flow — HP MAD, Psoriasis MD, HP Fasted/Fed
MilestonePF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution FastedPF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet FedPF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet FastedPF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet FedPF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet FastedPF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted
Started00546699147222222
Completed0053649764222222
Not completed0001020283000000
Withdrew: Adverse event0001020061000000
Withdrew: Non-compliance0000000001000000
Withdrew: Withdrawal by subject0000000111000000
Withdrew: Lost to follow-up0000000110000000
HP Washout 2
Participant flow — HP Washout 2
MilestonePF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution FastedPF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet FedPF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet FastedPF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet FedPF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet FastedPF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted
Started0000609000222222
Completed0000502000222222
Not completed0000107000000000
Withdrew: Lost to follow-up0000107000000000
HP MAD and Fasted/Fed
Participant flow — HP MAD and Fasted/Fed
MilestonePF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tablet Fasted, Tablet Fed, Solution FastedPF-06700841: 100 mg Solution Fasted, Tablet Fasted, Tablet FedPF-06700841: 100 mg Tablet Fed, Solution Fasted, Tablet FastedPF-06700841: 100 mg Tablet Fasted, Solution Fasted, Tablet FedPF-06700841: 100 mg Solution Fasted, Tablet Fed, Tablet FastedPF-06700841: 100 mg Tablet Fed, Tablet Fasted, Solution Fasted
Started0000502000222222
Completed0000402000222222
Not completed0000100000000000

Outcome measures

PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1
Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · millimeter of mercury (mmHg)
Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1
millimeter of mercury (mmHg)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Supine Systolic Blood Pressure (SBP): Baseline114.2 ± 11.97110.6 ± 6.70108.7 ± 7.76102.8 ± 6.62117.8 ± 9.54112.4 ± 12.26115.3 ± 5.99
Supine SBP: Change at Day 1-2.6 ± 6.40-8.1 ± 9.321.0 ± 8.179.5 ± 5.96-1.5 ± 4.642.1 ± 11.28-5.3 ± 7.91
Supine Diastolic blood pressure (DBP): Baseline64.0 ± 8.5567.0 ± 8.7766.2 ± 8.4258.7 ± 8.1970.3 ± 7.3966.9 ± 8.9870.5 ± 5.88
Supine DBP: Change at Day 1-1.1 ± 7.44-5.3 ± 9.052.2 ± 9.564.7 ± 7152.5 ± 8.83-0.1 ± 8.36-2.3 ± 6.14
PrimaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10
Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · mmHg
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Blood Pressure at Day 10
mmHgPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Supine SBP: Baseline (n=9,2,5,4,6,5,6)112.2 ± 9.78106.5 ± 3.54103.6 ± 7.64110.3 ± 5.19111.5 ± 13.35108.6 ± 18.45115.8 ± 8.66
Supine SBP: Change at Day 10 (n=9,2,5,3,6,4,4)4.0 ± 9.1212.5 ± 2.12-0.2 ± 7.698.7 ± 10.697.7 ± 12.97-3.5 ± 8.89-5.3 ± 4.86
Supine DBP: Baseline (n=9,2,5,4,6,5,6)60.3 ± 4.1561.5 ± 7.7856.2 ± 4.0265.5 ± 3.7068.8 ± 9.0659.2 ± 16.8066.2 ± 8.06
Supine DBP: Change at Day 10 (n=9,2,5,3,6,4,4)4.2 ± 7.266.0 ± 4.242.2 ± 6.765.7 ± 1.533.2 ± 9.62-4.3 ± 9.142.0 ± 5.48
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28
Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · mmHg
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Blood Pressure at Day 28
mmHgPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Supine SBP: Baseline (n =9, 14, 7)115.0 ± 13.21120.1 ± 10.91112.9 ± 8.11
Supine SBP: Change at Day 28 (n =8, 7, 5)-5.3 ± 11.87-8.9 ± 9.941.0 ± 11.94
Supine DBP: Baseline (n =9, 14, 7)67.8 ± 7.9369.9 ± 7.9466.6 ± 7.55
Supine DBP: Change at Day 28 (n =8, 7, 5)-3.9 ± 5.51-7.0 ± 6.00-0.8 ± 16.96
PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1
Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · beats per minute (bpm)
Single Ascending Dose (SAD) Cohort: Change From Baseline in Pulse Rate at Day 1
beats per minute (bpm)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline57.5 ± 6.3668.6 ± 13.8167.2 ± 9.6656.0 ± 8.0567.3 ± 9.2455.8 ± 11.7757.8 ± 6.54
Change at Day 11.0 ± 3.426.1 ± 7.582.5 ± 6.283.0 ± 8.100.7 ± 5.54-1.1 ± 3.942.6 ± 6.39
PrimaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10
Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · bpm
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Pulse Rate at Day 10
bpmPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9,2,5,4,6,5,6)59.3 ± 12.5859.0 ± 1.4155.8 ± 7.3660.8 ± 4.9961.5 ± 7.5066.0 ± 9.4360.5 ± 9.61
Change at Week 10 (n =9,2,5,3,6,4,4,)-2.3 ± 12.21-0.5 ± 0.71-1.6 ± 5.18-4.0 ± 7.21-6.3 ± 8.24-2.5 ± 4.43-1.0 ± 6.38
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28
Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · bpm
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Pulse Rate at Day 28
bpmPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)61.8 ± 8.0761.4 ± 9.5264.9 ± 6.04
Change at Week 28 (n =8, 7, 5)-1.9 ± 5.38-5.3 ± 7.41-3.0 ± 3.39
PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1
Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · degree celsius
Single Ascending Dose (SAD) Cohort: Change From Baseline in Oral Temperature at Day 1
degree celsiusPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline36.79 ± 0.15536.83 ± 0.35936.65 ± 0.18736.82 ± 0.19436.80 ± 0.14136.69 ± 0.16436.63 ± 0.149
Change at Day 10.05 ± 0.151-0.11 ± 0.4180.35 ± 0.2810.05 ± 0.2350.07 ± 0.103-0.03 ± 0.2380.05 ± 0.177
PrimaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10
Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · degree celsius
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Oral Temperature at Day 10
degree celsiusPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6)36.71 ± 0.13636.70 ± 0.14136.76 ± 0.18236.68 ± 0.12636.83 ± 0.16336.76 ± 0.16736.75 ± 0.235
Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)0.08 ± 0.2280.05 ± 0.071-0.22 ± 0.164-0.10 ± 0.100-0.22 ± 0.214-0.17 ± 0.2060.05 ± 0.208
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28
Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · degrees celsius
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Oral Temperature at Day 28
degrees celsiusPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n = 9, 14, 7)36.74 ± 0.15136.67 ± 0.21336.80 ± 0.277
Change at Week 28 (n= 8, 7, 5)0.01 ± 0.223-0.04 ± 0.369-0.20 ± 0.300
PrimaryNumber of Participants With Change From Baseline in Physical Examinations

Physical examinations included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.

Time frame:
SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Reported as:
Number · participants
Number of Participants With Change From Baseline in Physical Examinations
participantsPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Number of Participants With Change From Baseline in Physical Examinations00000000000000030000
PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1
Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · millisecond (msec)
Single Ascending Dose (SAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 1
millisecond (msec)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
PR Interval: Baseline175.7 ± 14.52149.7 ± 18.62163.1 ± 13.58168.2 ± 14.63163.6 ± 19.37175.8 ± 18.86165.9 ± 7.65
PR Interval: Change at Day 1-0.9 ± 6.786.7 ± 8.12-2.4 ± 6.652.2 ± 5.45-2.1 ± 5.953.3 ± 5.620.5 ± 7.54
QRS Complex: Baseline97.7 ± 15.4092.9 ± 9.3097.4 ± 10.43102.9 ± 8.7499.8 ± 14.61101.7 ± 6.8792.0 ± 5.81
QRS Complex: Change at Day 1-3.1 ± 12.73-1.5 ± 5.98-2.2 ± 4.06-1.7 ± 3.55-2.9 ± 3.45-2.0 ± 5.191.7 ± 2.33
QT Interval: Baseline408.4 ± 21.42374.0 ± 21.81384.3 ± 26.20404.2 ± 19.89387.5 ± 12.0421.3 ± 29.94407.1 ± 20.71
QT Interval: Change at Day 1-5.9 ± 10.41-3.8 ± 10.21-3.1 ± 9.43-8.2 ± 9.25-0.8 ± 4.56-0.8 ± 11.61-3.3 ± 14.78
QTC Interval: Baseline397.7 ± 16.51390.9 ± 20.95400.6 ± 11.90392.2 ± 13.42402.7 ± 20.69400.0 ± 7.60402.7 ± 14.10
QTC Interval: Change at Day 1-0.2 ± 9.24-2.3 ± 5.45-1.9 ± 7.612.4 ± 9.42-4.6 ± 4.414.2 ± 7.753.2 ± 5.76
PrimaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10
Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · msec
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 10
msecPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
PR Interval: Baseline (n =9,2,5,4,6,5,6)176.9 ± 16.31180.0 ± 1.41167.6 ± 10.69169.0 ± 22.38168.5 ± 18.79171.6 ± 14.77168.0 ± 6.66
PR Interval: Change at Day 10 (n =9,2,5,3,6,4,4)5.2 ± 3.594.7 ± 6.607.7 ± 5.3614.3 ± 8.417.3 ± 10.0711.2 ± 5.141.4 ± 2.33
QRS Complex: Baseline (n =9,2,5,4,6,5,6)96.6 ± 5.8396.0 ± 7.07103.0 ± 9.14101.0 ± 20.05102.7 ± 8.52103.0 ± 8.3495.2 ± 8.70
QRS Complex: Change at Day 10 (n =9,2,5,3,6,4,4)0.9 ± 1.60-0.5 ± 6.36-3.2 ± 9.49-2.3 ± 6.171.3 ± 5.322.9 ± 5.26-1.7 ± 1.83
QT Interval: Baseline (n =9,2,5,4,6,5,6)411.9 ± 27.98425.5 ± 10.61407.4 ± 18.17398.0 ± 9.56399.7 ± 16.12397.0 ± 23.29401.8 ± 27.66
QT Interval: Change at Day 10 (n =9,2,5,3,6,4,4)-3.9 ± 14.721.0 ± 11.79-1.0 ± 23.422.6 ± 9.261.3 ± 16.662.3 ± 5.512.1 ± 23.19
QTC Interval: Baseline (n =9,2,5,4,6,5,6)398.7 ± 11.35415.5 ± 4.95396.4 ± 15.53401.5 ± 15.37396.0 ± 6.54403.2 ± 6.26403.5 ± 11.96
QTC Interval: Change at Day 10 (n =9,2,5,3,6,4,4)-0.3 ± 9.82-1.5 ± 10.14-2.9 ± 3.00-5.0 ± 10.49-1.3 ± 10.34-0.3 ± 4.462.0 ± 10.47
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28
Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · msec
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) at Day 28
msecPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
PR Interval: Baseline (n =9, 14, 7)169.4 ± 15.26156.1 ± 17.78154.7 ± 11.51
PR Interval: Change at Day 28 (n =8, 7, 5)-0.6 ± 10.1911.1 ± 5.954.1 ± 7.09
QRS Complex: Baseline (n =9, 14, 7)100.6 ± 8.3297.4 ± 10.2793.0 ± 5.87
QRS Complex: Change at Day 28 (n= 8, 7, 5)0.5 ± 4.860.8 ± 4.733.8 ± 5.26
QT Interval: Baseline (n =9, 14, 7)404.4 ± 17.48411.6 ± 31.01379.0 ± 18.94
QT Interval: Change at Day 28 (n =8, 7, 5)-17.9 ± 16.00-22.6 ± 23.04-5.3 ± 9.43
QTC Interval: Baseline (n=9, 14, 7)409.7 ± 14.46409.0 ± 14.92392.0 ± 19.04
QTC Interval: Change at Day 28 (n= 8, 7, 5)-8.7 ± 10.83-9.6 ± 7.89-2.7 ± 13.18
PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1
Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · bpm
Single Ascending Dose (SAD) Cohort: Change From Baseline in Heart Rate at Day 1
bpmPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline56.1 ± 6.8370.3 ± 16.4669.2 ± 12.0655.3 ± 5.6567.7 ± 8.8253.0 ± 8.9258.0 ± 5.17
Change at Day 12.2 ± 3.741.6 ± 2.810.3 ± 3.274.6 ± 4.64-2.3 ± 1.722.0 ± 3.193.4 ± 5.79
PrimaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10
Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · bpm
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Heart Rate at Day 10
bpmPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6)55.1 ± 7.1555.5 ± 2.1255.4 ± 4.4561.0 ± 2.9458.5 ± 6.3863.0 ± 7.3861.2 ± 7.96
Change at Day 10 (n = 9, 2, 5, 3, 6, 4, 4)-1.2 ± 10.337.7 ± 6.13-1.1 ± 7.22-3.0 ± 4.04-2.3 ± 5.12-1.8 ± 5.79-1.3 ± 4.04
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28
Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · bpm
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Heart Rate at Day 28
bpmPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)63.1 ± 9.1560.2 ± 11.2566.0 ± 4.93
Change at Day 28 (n =8, 7, 5)5.2 ± 5.284.0 ± 8.731.4 ± 5.60
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the end of study (up to Day 8 in SAD cohort, Day 28 in MAD cohort, Day 56 in MAD Psoriasis cohort, Day 37 in Food effect cohort), that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.

Time frame:
SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs
participantsPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
AEs211013201323555116120
SAEs00000000000000000000
Withdrawal due to AEs00000000000000061000
PrimaryNumber of Adverse Events (AEs) According to Severity

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.

Time frame:
SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Reported as:
Number · adverse events
Number of Adverse Events (AEs) According to Severity
adverse eventsPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Mild2110140013226671616120
Moderate00000000000101000000
Severe00000000000000000000
PrimaryNumber of Participants With Laboratory Abnormalities

Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(\<) 0.8\*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: \<0.9\*LLN,\>1.1\*upper limit of normal (ULN); platelets: \<0.5\*LLN,\>1.75\*ULN, white blood cell count: \<0.6\*LLN, \>1.5\*ULN; lymphocytes, total neutrophils: \<0.8\*LLN, \>1.2\*ULN; eosinophils, basophils, monocytes: \>1.2\*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: \>1.1\*ULN; liver function: bilirubin: \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: \>3.0\*ULN; protein, albumin: \<0.8\*LLN\>\</0\>1.2\*ULN; renal function:blood urea nitrogen,creatinine: \>1.3\*ULN; uric acid: \>1.2\*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: \<0.9\*LLN,\>1.1\*ULN; urinalysis: pH\<4.5, \>8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: \<0.6\*LLN,\>1.5\*ULN)

Time frame:
SAD Cohort: Baseline up to Day 8, MAD Cohort: Baseline up to Day 28, MAD Psoriasis Cohort: Baseline up to Day 56, Food Effect Cohort: Baseline up to Day 37
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities
participantsPlacebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Number of Participants With Laboratory Abnormalities744666760546567137513
PrimarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1

Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

Time frame:
Baseline, 24 hours post-dose on Day 1
Reported as:
Mean · milliliter per minute (mL/min)
Single Ascending Dose (SAD) Cohort: Change From Baseline in Creatinine Clearance at Day 1
milliliter per minute (mL/min)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline117.7 ± 28.7093.0 ± 36.60133.8 ± 29.7695.8 ± 53.07117.0 ± 28.70129.6 ± 25.43114.4 ± 24.64
Change at Day 124.3 ± 63.75-0.4 ± 35.35-2.7 ± 11.2715.8 ± 36.79-6.4 ± 6.35-17.6 ± 28.6773.4 ± 227.50
PrimaryMultiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10

Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

Time frame:
Baseline, 16 hours post-dose on Day 10
Reported as:
Mean · mL/min
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 10
mL/minPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6, 2, 2, 7)114.4 ± 27.75111.0 ± 1.41112.6 ± 42.08115.0 ± 34.13142.5 ± 56.68138.4 ± 51.2783.0 ± 39.73140.5 ± 55.86158.0 ± 36.77172.4 ± 51.74
Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4, 2, 2, 7)0.7 ± 33.29-2.5 ± 57.2826.8 ± 46.90-19.0 ± 25.51-47.0 ± 55.68-39.5 ± 29.863.5 ± 40.42-38.5 ± 60.10-50.0 ± 4.24-67.3 ± 61.45
PrimaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28

Creatinine clearance is a measure of kidney function. Creatinine clearance is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time.

Time frame:
Baseline, 16 hours post-dose on Day 28
Reported as:
Mean · mL/min
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28
mL/minPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Creatinine Clearance at Day 28-10.0 ± 0.0-35.0 ± 33.94-67.6 ± 50.33
PrimaryFood Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841
nanogram*hour per milliliter (ng*hr/mL)PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Food Effect Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-067008416463 ± 466720 ± 435321 ± 53
PrimaryFood Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841

Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).

Time frame:
pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841
ng*hr/mLPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Food Effect Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-067008416447 ± 466694 ± 435305 ± 53
PrimaryFood Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
Time frame:
pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
nanogram per milliliter (ng/mL)PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Food Effect Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-067008411022 ± 351084 ± 40656.6 ± 26
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
Time frame:
SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Reported as:
Geometric mean · ng/mL
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-06700841
ng/mLPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Maximum Observed Plasma Concentration (Cmax) of PF-067008415.138 ± 5218.21 ± 9279.30 ± 35271.3 ± 21748.4 ± 352460 ± 3763.42 ± 11286.6 ± 17734.1 ± 29522.0 ± 312091 ± 28204.7 ± 43924.2 ± 13
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841
Time frame:
SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Reported as:
Median · hour
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06700841
hourPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-067008411.00 (0.500 to 2.00)1.00 (0.500 to 1.00)0.500 (0.500 to 1.00)1.00 (0.500 to 1.02)1.00 (0.500 to 2.00)1.00 (0.500 to 2.00)1.00 (1.00 to 1.03)1.00 (1.00 to 1.00)1.50 (1.00 to 2.00)1.00 (1.00 to 2.00)0.984 (0.500 to 2.00)1.00 (0.983 to 1.00)2.00 (1.00 to 2.00)
SecondaryFood Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841
Time frame:
Pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post dose on Day 1
Reported as:
Median · hour
Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--06700841
hourPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Food Effect Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF--067008410.500 ± 0.5001.00 ± 1.29654.00 ± 1.4383
SecondarySingle Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

Time frame:
pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841
ng*hr/mLPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06700841NA ± NA145.8 ± 61353.8 ± 311439 ± 654797 ± 6218410 ± 46
SecondaryMultiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841

Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.

Time frame:
MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Reported as:
Geometric mean · ng*hr/mL
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841
ng*hr/mLPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06700841422.8 ± 411880 ± 526089 ± 383560 ± 3516180 ± 15990.0 ± 1037672 ± 43
SecondarySingle Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841

Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast).

Time frame:
pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-06700841
ng*hr/mLPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-0670084117.71 ± 11479.18 ± 239340.4 ± 301431 ± 655041 ± 5918400 ± 46
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841

Dose normalized (dn) Cmax was calculated by dividing Cmax by the exact dose of PF 06700841 (in mg) administered to a participant.

Time frame:
SAD: pre-dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post dose on Day 1; MAD: pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5,1,2,4,6,8,12,16,24 hours post dose on Day 28
Reported as:
Geometric mean · [nanogram/milliliter]/milligram
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06700841
[nanogram/milliliter]/milligramPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-067008415.138 ± 526.061 ± 927.930 ± 359.033 ± 217.484 ± 3512.31 ± 376.342 ± 119.563 ± 177.341 ± 2910.43 ± 3011.97 ± 286.827 ± 439.242 ± 13
SecondarySingle Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). AUCinf(dn) was calculated by dividing AUCinf by the exact dose of PF-06700841 (in mg) administered to a participant.

Time frame:
pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Reported as:
Geometric mean · [nanogram*hour/milliliter]/milligram
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841
[nanogram*hour/milliliter]/milligramPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of PF-06700841NA ± NA48.65 ± 6135.38 ± 3147.97 ± 6547.97 ± 6292.13 ± 46
SecondarySingle Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841

Area under the plasma concentration time-curve from time zero to the time of last measured concentration (AUClast). AUClast(dn) was calculated by dividing AUClast by the exact dose of of PF-06700841 (in mg) administered to a participant.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post dose on Day 1
Reported as:
Geometric mean · [ng*hr/mL]/mg
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06700841
[ng*hr/mL]/mgPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-0670084117.71 ± 11426.38 ± 23934.04 ± 3047.64 ± 6550.41 ± 5992.09 ± 46
SecondaryMultiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841

Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort. AUCtau(dn) was calculated by dividing AUCtau by the exact dose of of PF-06700841 (in mg) administered to a participant.

Time frame:
pre-dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10
Reported as:
Geometric mean · [ng*hr/mL]/mg
Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-06700841
[ng*hr/mL]/mgPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Multiple Ascending Dose (MAD) Cohort: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of PF-0670084142.28 ± 4162.68 ± 5160.89 ± 3871.15 ± 3692.30 ± 16
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841

Plasma decay half-life is the time measured for the plasma concentration of PF-06700841 to decrease by one half.

Time frame:
SAD: pre--dose, 0.5,1,2,4,6,8,12,16,24,36,48,72,96 hour post-dose on Day 1; MAD: pre--dose 0.5,1,2,4,6,8,12,24 hour post-dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28
Reported as:
Mean · hour
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841
hourPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Plasma Decay Half-Life (t1/2) of PF-06700841NA ± NA4.554 ± 1.80663.848 ± 1.15874.363 ± 2.41267.519 ± 2.82366.813 ± 1.98755.928 ± 3.33364.860 ± 1.930410.67 ± 1.84409.133 ± 2.25797.458 ± 2.159516.01 ± 31.5846.032 ± 1.71216.155 ± 1.44086.168 ± 1.29655.848 ± 1.4383
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841

MRT= AUMCinf/AUCinf, where AUMCinf is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method.

Time frame:
SAD: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Reported as:
Geometric mean · hour
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841
hourPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Mean Residence Time (MRT) of PF-06700841NA ± NA6.414 ± 465.169 ± 345.206 ± 447.277 ± 378.758 ± 297.191 ± 456.830 ± 3810.35 ± 259.592 ± 229.025 ± 266.072 ± 928.534 ± 36
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Reported as:
Mean · liter
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841
literPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Volume of Distribution (Vz/F) of PF-06700841NA ± NA126.4 ± 26151.0 ± 18115.7 ± 16210.5 ± 45102.4 ± 27177.6 ± 30106.2 ± 12249.4 ± 45180.9 ± 30112.4 ± 18245.4 ± 206109.6 ± 18
SecondarySingle Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Clearance obtained after oral dose is influenced by the fraction of the dose absorbed. CL/F =Dose of PF-06700841/AUCinf.

Time frame:
SAD: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hour post-dose on Day 1; MAD: pre-dose 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hour post-dose on Day 10; MAD Psoriasis: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose on Day 28
Reported as:
Geometric mean · Liter per hour (L/hr)
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841
Liter per hour (L/hr)PF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Apparent Clearance (CL/F) of PF-06700841NA ± NA20.57 ± 6128.26 ± 3120.82 ± 6520.85 ± 6110.86 ± 4623.65 ± 4115.95 ± 5116.43 ± 3814.03 ± 3510.83 ± 1630.30 ± 10313.04 ± 43
SecondaryMultiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841

PTF was calculated as: Cmax-Cmin/Cavg. Cmax is the maximum observed plasma concentration of PF-06700841. Cmin is the minimum observed plasma concentration of PF-06700841. Cavg is the average observed plasma concentration of PF-06700841 calculated as area under the plasma concentration-time curve during a dosing Interval (AUC\[tau\]) divided by the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort and 24 hours for MAD Psoriasis cohort.

Time frame:
MAD: pre--dose 0.5, 1, 2, 4, 6, 8, 12, 24 hour post--dose on Day 10; MAD Psoriasis: pre--dose, 0.5,1,2,4,6,8,12,16,24 hours post-dose on Day 28
Reported as:
Geometric mean · ratio
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-06700841
ratioPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Multiple Ascending Dose (MAD) and MAD Psoriasis Cohort: Peak-Trough Fluctuation (PTF) of PF-067008412.815 ± 403.543 ± 382.643 ± 311.297 ± 222.911 ± 433.414 ± 442.654 ± 42
SecondaryMultiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)

Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

Time frame:
0-24 hour on Day 10
Reported as:
Geometric mean · milligram
Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)
milligramPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Multiple Ascending Dose (MAD) Cohort: Amount of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau)1.109 ± 452.798 ± 57NA ± NA7.758 ± 5715.60 ± 44
SecondaryMultiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)

Aetau% was calculated as: 100\*Aetau/dose. Aetau is the amount of drug recovered unchanged in urine during the dosing interval (tau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

Time frame:
0-24 hours on Day 10
Reported as:
Geometric mean · percentage of dose recovered
Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)
percentage of dose recoveredPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Multiple Ascending Dose (MAD) Cohort: Percentage of Dose of PF-06700841 Recovered Unchanged in the Urine Over the Time Interval Tau (Aetau%)11.09 ± 459.332 ± 57NA ± NA15.54 ± 578.910 ± 44
SecondaryMultiple Ascending Dose (MAD) Cohort: Renal Clearance

Renal clearance was calculated as amount of drug recovered unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours for MAD once daily cohorts, 12 hours for MAD twice daily cohort.

Time frame:
0-24 hours on Day 10
Reported as:
Geometric mean · Liter per hour
Multiple Ascending Dose (MAD) Cohort: Renal Clearance
Liter per hourPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Multiple Ascending Dose (MAD) Cohort: Renal Clearance2.619 ± 181.486 ± 15NA ± NA2.179 ± 310.9629 ± 58
SecondarySingle Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline

Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.

Time frame:
Baseline
Reported as:
Mean · picogram per milliliter (pg/mL)
Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline
picogram per milliliter (pg/mL)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Baseline119.17 ± 40.090188.76 ± 238.380219.62 ± 275.44078.28 ± 29.481141.38 ± 100.403115.00 ± 38.458114.33 ± 26.164
SecondaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28

Serum samples for IP-10 were analyzed using a validated analytical assay. LLOQ for IP-10 was 10 pg/mL.

Time frame:
Baseline, Day 2, 5, 10, 11, 28
Reported as:
Mean · pg/mL
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Interferon Gamma-induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 10, 11, 28
pg/mLPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6)114.04 ± 70.65885.50 ± 13.011101.12 ± 56.853142.23 ± 165.924106.43 ± 28.244121.60 ± 20.959135.42 ± 57.855
Change at Day 2 (n =9, 2, 5, 4, 6, 5, 6)5.66 ± 13.4212.00 ± 13.294-20.14 ± 41.966-23.60 ± 82.888-47.52 ± 19.664-60.64 ± 16.913-67.73 ± 35.998
Change at Day 5 (n =9, 2, 5, 4, 6, 5, 6)4.33 ± 12.213-3.25 ± 13.506-42.12 ± 48.250-53.40 ± 125.815-55.80 ± 15.273-71.40 ± 11.857-80.65 ± 66.445
Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)-1.92 ± 24.1234.75 ± 9.687-40.10 ± 43.129-96.67 ± 134.176-57.22 ± 9.321-70.50 ± 14.007-106.40 ± 60.163
Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)11.01 ± 19.0081.85 ± 0.778-37.56 ± 47.031-102.53 ± 131.223-37.95 ± 24.957-54.25 ± 23.972-112.20 ± 60.459
Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)-14.59 ± 21.7362.85 ± 11.102-11.76 ± 51.955-62.07 ± 94.3788.48 ± 23.01018.30 ± 34.748-47.15 ± 89.356
SecondaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56

Serum samples for IP-10 were analyzed using a validated analytical assay. Lower limit of quantification (LLOQ) for IP-10 was 10 pg/mL.

Time frame:
Baseline, Day 2, 5, 7, 14, 21, 28, 29, 35, 56
Reported as:
Mean · pg/mL
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Interferon Gamma-Induced Protein 10 (IP-10) Concentration in Serum at Day 2, 5, 7, 14, 21, 28, 29, 35, 56
pg/mLPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)302.00 ± 281.552127.58 ± 45.829123.09 ± 22.244
Change at Day 2 (n =9, 14, 7)53.44 ± 214.334-8.51 ± 34.704-49.57 ± 35.759
Change at Day 5 (n =9, 14, 7)-21.63 ± 142.195-33.93 ± 33.465-49.01 ± 35.998
Change at Day 7 (n =9, 12, 7)-25.71 ± 133.510-31.31 ± 32.203-52.50 ± 42.216
Change at Day 14 (n =9, 10, 6)-69.91 ± 106.951-52.06 ± 24.663-68.55 ± 28.524
Change at Day 21 (n =9, 9, 5)-42.87 ± 122.986-51.47 ± 28.094-46.64 ± 27.340
Change at Day 28 (n =8, 7, 5)-1.0 ± 31.351-46.19 ± 35.893-53.36 ± 19.771
Change at Day 29 (n =8, 7, 5)-22.20 ± 95.930-37.50 ± 31.849-49.34 ± 14.306
Change at Day 35 (n =8, 6, 5)-69.54 ± 124.16510.45 ± 37.860110.68 ± 108.041
Change at Day 56 (n =7, 6, 4)-31.71 ± 67.15816.18 ± 19.348167.85 ± 201.780
SecondarySingle Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline

Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

Time frame:
Baseline
Reported as:
Mean · milligram per deciliter (mg/dL)
Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline
milligram per deciliter (mg/dL)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Single Ascending Dose (SAD) Cohort: High Sensitivity C-reactive Protein (hsCRP) Concentration in Serum at Baseline0.1220 ± 0.119090.1066 ± 0.096620.6420 ± 1.414130.0757 ± 0.045230.2290 ± 0.117140.1158 ± 0.208710.1710 ± 0.10387
SecondaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28

Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

Time frame:
Baseline, Day 2, 5, 10, 11, 28
Reported as:
Mean · mg/dL
Multiple Ascending Dose (MAD) Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 10, 11, 28
mg/dLPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n= 9, 2, 5, 4, 6, 5, 6)0.0974 ± 0.067910.0815 ± 0.085560.1002 ± 0.116750.0983 ± 0.037340.0505 ± 0.027990.0746 ± 0.025230.1902 ± 0.06394
Change at Day 2 (n= 9, 2, 5, 4, 6, 5, 6)-0.0148 ± 0.03176-0.0205 ± 0.00071-0.0670 ± 0.08196-0.0408 ± 0.03052-0.0212 ± 0.01712-0.0298 ± 0.01743-0.0307 ± 0.08168
Change at Day 5 (n= 9, 2, 5, 4, 6, 5, 6)-0.0352 ± 0.03847-0.0050 ± 0.02263-0.0972 ± 0.11656-0.0753 ± 0.02269-0.0435 ± 0.02202-0.0596 ± 0.03345-0.1078 ± 0.05948
Change at Day 10 (n= 9, 2, 5, 3, 6, 4, 4)-0.0329 ± 0.056560.0015 ± 0.00778-0.1002 ± 0.11675-0.0903 ± 0.00961-0.0467 ± 0.02881-0.0618 ± 0.01445-0.1838 ± 0.04529
Change at Day 11 (n= 9, 2, 5, 3, 6, 4, 4)-0.0186 ± 0.07315-0.0040 ± 0.00990-0.1002 ± 0.11675-0.0870 ± 0.00819-0.0435 ± 0.02849-0.0615 ± 0.01330-0.1878 ± 0.04136
Change at Day 28 (n= 9, 2, 5, 3, 6, 4, 4)0.0496 ± 0.187480.0790 ± 0.08910-0.0352 ± 0.150330.0023 ± 0.060010.0223 ± 0.01556-0.0275 ± 0.040861.1255 ± 1.63253
SecondaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56

Serum samples for hsCRP were analyzed using a validated analytical assay. Reference range for measurement of CRP was 0.015 to 2.0 mg/dL. LLOQ for hsCRP was 0.03 mg/dL and limit of detection was 0.015 mg/dL.

Time frame:
Baseline, Day 2, 5 ,7,14, 21, 28, 29, 35, 56
Reported as:
Mean · mg/dL
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline In High Sensitivity C-reactive Protein (hsCRP) at Day 2, 5, 7, 14, 21, 28, 29, 35 and 56
mg/dLPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)1.0699 ± 1.391790.5694 ± 1.117520.3143 ± 0.34167
Change at Day 2 (n =9, 14, 7)-0.1096 ± 0.25370-0.3408 ± 0.86901-0.0189 ± 0.14180
Change at Day 5 (n =9, 14, 7)0.0204 ± 0.51424-0.2413 ± 1.45363-0.2119 ± 0.27245
Change at Day 7 (n =9, 12, 7)0.1958 ± 0.85725-0.1573 ± 1.90640-0.1983 ± 0.31021
Change at Day 14 (n =9, 10, 6)0.4118 ± 1.19190-0.1910 ± 0.65215-0.2582 ± 0.33762
Change at Day 21 (n =9, 9, 5)-0.1397 ± 0.46958-0.3067 ± 0.61035-0.2716 ± 0.38954
Change at Day 28 (n =8, 7, 5)-0.4075 ± 0.37814-0.3549 ± 0.69576-0.2670 ± 0.37674
Change at Day 29 (n =8, 7, 5)-0.6113 ± 0.79373-0.3533 ± 0.69589-0.2626 ± 0.34387
Change at Day 35 (n =8, 6, 5)-0.5945 ± 0.78042-0.2533 ± 0.794460.7546 ± 1.07215
Change at Day 56 (n =7, 6, 4)-0.3407 ± 0.45280-0.2662 ± 0.783070.2533 ± 0.82107
SecondarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8
Time frame:
Baseline, Day 2, 5, 8
Reported as:
Mean · cells per millimeter cube (cells/mm^3)
Single Ascending Dose (SAD) Cohort: Change From Baseline in Neutrophil Counts at Day 2, 5 and 8
cells per millimeter cube (cells/mm^3)Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline (n =13, 7, 6, 6, 6, 8, 8)2.988 ± 1.20902.433 ± 1.05743.097 ± 1.19032.500 ± 0.67823.048 ± 0.75522.973 ± 1.23742.858 ± 0.6901
Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)0.096 ± 0.74590.340 ± 0.66430.377 ± 0.71330.285 ± 0.32140.240 ± 0.7344-0.315 ± 0.8594-0.760 ± 0.5266
Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)0.047 ± 0.80480.280 ± 0.5187-0.162 ± 1.1032-0.170 ± 0.2265-0.170 ± 0.69630.296 ± 0.38490.654 ± 0.6930
Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)-0.245 ± 0.78340.196 ± 0.16740.017 ± 1.1173-0.293 ± 0.3100-0.058 ± 0.9051-0.110 ± 0.79101.188 ± 1.8134
SecondaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28
Time frame:
Baseline, Day 4, 8, 10, 11, 14, 28
Reported as:
Mean · cells/mm^3
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Neutrophil Counts at Day 4, 8, 10, 11, 14, 28
cells/mm^3Placebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6)2.584 ± 0.88582.340 ± 0.29702.676 ± 0.67262.770 ± 0.49072.710 ± 1.03722.690 ± 0.93373.217 ± 0.9677
Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)0.099 ± 0.41910.060 ± 0.0283-0.242 ± 1.1533-0.215 ± 0.6376-0.295 ± 0.8000-0.980 ± 0.3726-0.902 ± 2.0680
Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)0.239 ± 0.57250.635 ± 1.1526-0.296 ± 0.7032-0.178 ± 0.5160-0.793 ± 0.5720-0.913 ± 0.4039-1.702 ± 1.3292
Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)0.156 ± 0.58600.635 ± 1.0394-0.340 ± 0.86020.327 ± 0.8228-1.012 ± 0.5365-1.168 ± 0.4197-2.125 ± 1.2878
Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)0.158 ± 0.49960.400 ± 1.2021-0.382 ± 0.82440.260 ± 0.7572-0.280 ± 0.9159-0.248 ± 0.3976-2.010 ± 1.3075
Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)-0.020 ± 0.54710.385 ± 0.8273-0.060 ± 0.86630.650 ± 0.85430.232 ± 0.43950.228 ± 0.33770.290 ± 1.0943
Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)0.030 ± 0.46490.130 ± 0.4525-0.012 ± 1.14010.697 ± 0.0839-0.055 ± 0.45780.050 ± 0.62490.298 ± 0.3777
SecondaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
Time frame:
Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56
Reported as:
Mean · cells/mm^3
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Neutrophil Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
cells/mm^3Placebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)4.109 ± 1.44013.640 ± 1.49973.909 ± 1.1841
Change at Day 4 (n =9, 14, 7)-0.402 ± 0.93080.006 ± 1.16960.153 ± 0.7114
Change at Day 6 (n =9, 14, 7)-0.209 ± 1.2224-0.073 ± 0.8229-0.303 ± 0.6058
Change at Day 8 (n =9, 12, 7)-0.473 ± 0.69620.013 ± 1.2572-0.973 ± 0.4394
Change at Day 10 (n =9, 10, 7)-0.463 ± 0.78340.197 ± 1.1099-1.299 ± 0.6906
Change at Day 13 (n =9, 10, 6)-0.654 ± 0.7847-0.297 ± 1.2264-1.538 ± 0.9097
Change at Day 14 (n =9, 10, 6)-0.247 ± 0.9682-0.146 ± 1.1226-1.465 ± 0.9517
Change at Day 21 (n =9, 9, 5)-0.762 ± 0.7389-0.638 ± 0.9404-1.410 ± 1.2572
Change at Day 28 (n =8, 7, 5)-0.678 ± 0.6416-0.890 ± 0.9952-1.450 ± 1.1195
Change at Day 35 (n =8, 6, 5)-0.081 ± 1.4496-0.777 ± 1.1154-1.008 ± 0.8082
Change at Day 42 (n =7, 6, 4)-0.427 ± 0.6004-0.677 ± 1.1209-1.050 ± 0.6868
Change at Day 56 (n =7, 6, 4)-0.036 ± 0.7864-0.533 ± 1.3025-0.493 ± 1.6373
SecondarySingle Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8
Time frame:
Baseline, Day 2, 5, 8
Reported as:
Mean · cells/mm^3
Single Ascending Dose (SAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 2, 5, 8
cells/mm^3Placebo: SAD CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 200 mg SAD Cohort
Baseline (n =13, 7, 6, 6, 6, 8, 8)1.23 ± 0.4701.19 ± 0.3800.98 ± 0.2791.25 ± 0.2431.25 ± 0.3271.44 ± 0.8251.20 ± 0.524
Change at Day 2 (n =13, 7, 6, 6, 6, 8, 8)0.02 ± 0.152-0.09 ± 0.135-0.02 ± 0.160-0.15 ± 0.1380.02 ± 0.256-0.14 ± 0.177-0.16 ± 0.177
Change at Day 5 (n =13, 6, 6, 6, 5, 8, 8)0.04 ± 0.1940.07 ± 0.175-0.05 ± 0.138-0.27 ± 0.1030.02 ± 0.409-0.23 ± 0.459-0.15 ± 0.193
Change at Day 8 (n =12, 5, 6, 6, 5, 8, 8)0.03 ± 0.2340.04 ± 0.1140.03 ± 0.242-0.15 ± 0.2260.34 ± 0.532-0.26 ± 0.478-0.14 ± 0.346
SecondaryMultiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28
Time frame:
Baseline, Day 4, 8, 10, 11, 14, 28
Reported as:
Mean · cells/mm^3
Multiple Ascending Dose (MAD) Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 8, 10, 11, 14 and 28
cells/mm^3Placebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 175 mg Once Daily MAD Cohort
Baseline (n =9, 2, 5, 4, 6, 5, 6)1.26 ± 0.4900.85 ± 0.2121.22 ± 0.3631.03 ± 0.3501.40 ± 0.4102.26 ± 0.5501.38 ± 0.286
Change at Day 4 (n =9, 2, 5, 4, 6, 5, 6)-0.03 ± 0.2120.05 ± 0.071-0.10 ± 0.0710.05 ± 0.129-0.18 ± 0.306-0.54 ± 0.241-0.32 ± 0.223
Change at Day 8 (n =9, 2, 5, 4, 6, 4, 5)-0.11 ± 0.2850.30 ± 0.283-0.20 ± 0.100-0.13 ± 0.250-0.60 ± 0.210-1.28 ± 0.395-0.90 ± 0.187
Change at Day 10 (n =9, 2, 5, 3, 6, 4, 4)-0.19 ± 0.3980.20 ± 0.283-0.24 ± 0.089-0.07 ± 0.231-0.70 ± 0.352-1.48 ± 0.403-0.93 ± 0.206
Change at Day 11 (n =9, 2, 5, 3, 6, 4, 4)-0.13 ± 0.3430.30 ± 0.424-0.34 ± 0.089-0.23 ± 0.115-0.72 ± 0.354-1.43 ± 0.499-0.93 ± 0.330
Change at Day 14 (n =9, 2, 5, 3, 6, 4, 4)-0.12 ± 0.3930.05 ± 0.495-0.22 ± 0.1100.03 ± 0.058-0.60 ± 0.297-1.10 ± 0.408-0.90 ± 0.183
Change at Day 28 (n =9, 2, 5, 3, 6, 4, 4)0.11 ± 0.431-0.05 ± 0.2120.22 ± 0.2770.30 ± 0.3460.65 ± 0.6190.18 ± 0.1890.33 ± 0.479
SecondaryMultiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
Time frame:
Baseline, Day 4, 6 ,8,10, 13, 14, 21, 28, 35, 42, 56
Reported as:
Mean · cells/mm^3
Multiple Ascending Dose (MAD) Psoriasis Cohort: Change From Baseline in Reticulocyte Counts at Day 4, 6, 8, 10, 13, 14, 21, 28, 35, 42 and 56
cells/mm^3Placebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis Cohort
Baseline (n =9, 14, 7)1.49 ± 0.3551.45 ± 0.2851.31 ± 0.393
Change at Day 4 (n =9, 14, 7)-0.10 ± 0.300-0.09 ± 0.207-0.13 ± 0.281
Change at Day 6 (n =9, 14, 7)-0.09 ± 0.392-0.16 ± 0.250-0.27 ± 0.373
Change at Day 8 (n =9, 12, 7)-0.20 ± 0.430-0.21 ± 0.243-0.59 ± 0.353
Change at Day 10 (n =9, 10, 7)-0.21 ± 0.355-0.35 ± 0.295-0.70 ± 0.361
Change at Day 13 (n =9, 10, 6)-0.20 ± 0.354-0.41 ± 0.373-0.75 ± 0.459
Change at Day 14 (n =9, 10, 6)-0.13 ± 0.371-0.34 ± 0.392-0.82 ± 0.462
Change at Day 21 (n =9, 9, 5)-0.22 ± 0.393-0.27 ± 0.430-0.66 ± 0.270
Change at Day 28 (n =8, 7, 5)-0.24 ± 0.487-0.36 ± 0.264-0.60 ± 0.255
Change at Day 35 (n =8, 6, 5)0.26 ± 0.498-0.03 ± 0.1630.22 ± 0.228
Change at Day 42 (n =7, 6, 4)0.46 ± 0.4310.33 ± 0.4271.35 ± 0.551
Change at Day 56 (n =7, 6, 40.13 ± 0.3350.07 ± 0.2500.50 ± 0.183

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: SAD Cohort—0/13 (0%)2/13 (15.4%)
Placebo: Once Daily MAD Cohort—0/9 (0%)0/9 (0%)
Placebo: Twice Daily MAD Cohort—0/2 (0%)1/2 (50%)
Placebo: MAD Psoriasis Cohort—0/9 (0%)5/9 (55.6%)
PF--06700841: 1 Milligram (mg) SAD Cohort—0/7 (0%)1/7 (14.3%)
PF--06700841: 3 mg SAD Cohort—0/6 (0%)1/6 (16.7%)
PF-06700841: 10 mg SAD Cohort—0/6 (0%)0/6 (0%)
PF-06700841: 10 mg Once Daily MAD Cohort—0/5 (0%)3/5 (60%)
PF-06700841: 30 mg SAD Cohort—0/6 (0%)1/6 (16.7%)
PF-06700841: 30 mg Once Daily MAD Cohort—0/4 (0%)2/4 (50%)
PF-06700841: 100 mg SAD Cohort—0/8 (0%)3/8 (37.5%)
PF-06700841: 100 mg Once Daily MAD Cohort—0/6 (0%)3/6 (50%)
PF-06700841: 50 mg Twice Daily MAD Cohort—0/5 (0%)5/5 (100%)
PF-06700841: 200 mg SAD Cohort—0/8 (0%)2/8 (25%)
PF-06700841: 175 mg Once Daily MAD Cohort—0/6 (0%)5/6 (83.3%)
PF-06700841: 30 mg MAD Psoriasis Cohort—0/14 (0%)11/14 (78.6%)
PF-06700841: 100 mg MAD Psoriasis Cohort—0/7 (0%)6/7 (85.7%)
PF-06700841: 100 mg Tab Fasted (Food Effect Cohort)—0/12 (0%)1/12 (8.3%)
PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)—0/12 (0%)2/12 (16.7%)
PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)—0/12 (0%)0/12 (0%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlacebo: SAD CohortPlacebo: Once Daily MAD CohortPlacebo: Twice Daily MAD CohortPlacebo: MAD Psoriasis CohortPF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF-06700841: 10 mg SAD CohortPF-06700841: 10 mg Once Daily MAD CohortPF-06700841: 30 mg SAD CohortPF-06700841: 30 mg Once Daily MAD CohortPF-06700841: 100 mg SAD CohortPF-06700841: 100 mg Once Daily MAD CohortPF-06700841: 50 mg Twice Daily MAD CohortPF-06700841: 200 mg SAD CohortPF-06700841: 175 mg Once Daily MAD CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Tab Fasted (Food Effect Cohort)PF-06700841: 100 mg Solution Fasted (Food Effect Cohort)PF-06700841: 100 mg Tablet Fed (Food Effect Cohort)
Blood creatinine increasedInvestigations0/130/90/21/90/70/60/61/50/61/41/81/64/51/84/67/146/70/120/120/12
Skin irritationSkin and subcutaneous tissue disorders0/130/91/20/90/70/60/60/50/60/40/80/60/50/80/60/141/70/120/120/12
Neutrophil count decreasedInvestigations0/130/90/20/90/70/60/60/50/60/40/80/62/50/81/61/141/70/120/120/12
ConstipationGastrointestinal disorders0/130/90/23/90/70/60/60/50/60/41/80/60/50/81/63/140/70/120/120/12
PresyncopeNervous system disorders0/130/90/20/90/70/60/60/50/61/41/80/60/50/80/60/140/70/120/120/12
Upper respiratory tract infectionInfections and infestations0/130/90/20/90/70/60/61/50/60/40/81/60/50/80/60/141/70/120/120/12
SyncopeNervous system disorders0/130/90/20/90/70/60/61/50/60/40/80/60/50/80/60/140/70/120/120/12
NeutropeniaBlood and lymphatic system disorders0/130/90/20/90/70/60/60/50/60/40/80/60/50/81/60/140/70/120/120/12
HeadacheNervous system disorders0/130/90/20/90/71/60/60/50/60/40/81/60/51/80/61/141/70/121/120/12
HaematomaVascular disorders0/130/90/20/90/70/60/60/51/60/40/80/60/50/80/60/140/70/120/120/12

Baseline characteristics

Age, Customized
Age, Customized(participants)PF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Food Effect CohortTotal
18-44 Years42145611665555
45-64 Years3452322382741
Gender
Gender(Participants)PF--06700841: 1 Milligram (mg) SAD CohortPF--06700841: 3 mg SAD CohortPF--06700841: 10 mg SAD Cohort Then MAD CohortPF-06700841: 30 mg SAD Cohort Then MAD CohortPF--06700841: 100 mg SAD, 100 mg MAD, 50 mg MAD CohortPF--06700841: 200 mg SAD Cohort, 175 mg MAD CohortPlacebo: SAD Cohort Then MAD CohortPlacebo: MAD Psoriasis CohortPF-06700841: 30 mg MAD Psoriasis CohortPF-06700841: 100 mg MAD Psoriasis CohortPF-06700841: 100 mg Food Effect CohortTotal
Female000001112016
Male7666871281271190
08

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
09

References and documents

Publications

  • Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1447-1456. doi: 10.1002/cpdd.1163. Epub 2022 Aug 31. PubMed 36045513 ↗
  • Page KM, Suarez-Farinas M, Suprun M, Zhang W, Garcet S, Fuentes-Duculan J, Li X, Scaramozza M, Kieras E, Banfield C, Clark JD, Fensome A, Krueger JG, Peeva E. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4. doi: 10.1016/j.jid.2019.11.027. Epub 2020 Jan 21. PubMed 31972249 ↗
  • Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21. PubMed 29266308 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2014
First posted
Dec 8, 2014
Start
Nov 2014
Primary completionActual
Jan 2016
CompletionActual
Feb 2016
Results first posted
Mar 8, 2017
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02310750
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Nov 2014
Primary completion
Jan 2016
Completion
Feb 2016
Results posted
Mar 8, 2017
Last update
Mar 8, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion